Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573779 | 0.84 | ADORA3 (0.48) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574040 | 0.83 | ADORA3 (0.43) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29575041 | 0.82 | ADORA2A (0.49) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL29573444 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29574445 | 0.82 | ADORA3 (0.36) | ADORA3ADORA1ADORA2A | |
| SCHEMBL23201580 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL15935852 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL12509356 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573759 | 0.82 | ADORA3 (0.44) | ADORA3ADORA1ADORA2ATMIGD3HTR2C | |
| SCHEMBL29573946 | 0.82 | ADORA3 (0.40) | ADORA3ADORA1ADORA2ATMIGD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4196219-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | Biointervene, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022040241-A1 | A3 ADENOSINE RECEPTOR AGONISTS FOR USE IN MEDICINE | BIOINTERVENE, INC. (US) | 2022-02-24 | — | — | WO | disclosed |